In the venture capital arena, Third Rock Ventures launched Global Blood Therapeutics with a $40.7 million Series A financing.  Its lead program focuses on Sickle Cell Disease SCD), one of the earliest rare genetic diseases  defined on a molecular basis.  With 100,000 patients in the U.S. and more than 15 million worldwide, SCD is a health care challenge with few treatment options and no therapies to address the underlying cause. That may change.
While the IPO for Facebook (NYSE: FB) was all the talk in June, biopharmaceutical company Tesaro (NASDAQ: TSRO) priced 6 million shares at $13.50 per share, the mid-point of estimates for its IPO. The shares closed up slightly higher in their first day of trading. Tesaro focuses on developing treatments for cancer. Meanwhile, GlobeImmune filed to go public to raise up to $69 million. The company focuses on developing treatments for cancer and infectious diseases………Want to read more? Click here for a free trial to The Health Care M&A Information Source and download the current issue today